Google+ Facebook Twitter Twitter

"Childhood vaccines enhance cancer treatment"

Scientists claim new research shows that pre-immunisation, acquired through common childhood vaccines, can be used to enhance therapeutic cancer treatment.

The University of Helsinki team discovered that when animals were pre-immunised with an ordinary vaccine (for example, anti-tetanus), engrafted with tumour and then treated with the new hybrid viral platform called PeptiCRAd, they showed a dramatic improvement in tumour-specific immune response.

As a consequence of this, there was significantly improved anti-tumour efficacy.

Research lead Professor Vincenzo Cerullo claimed this approach can be easily translated into clinical trials, as it relies on pre-existing immunity of vaccines included in the national vaccination programs worldwide.

He said: “This method has potential to have a significant impact on current immunotherapy protocols.”

Due to the high coverage of international vaccination programmes, the majority of the worldwide population has been vaccinated against common pathogens, leading to a pathogen-specific immunological memory.

This is able to deploy a much faster and more effective immune response when we re-encounter the pathogens. This is called secondary response and it is stronger and faster than the first time we encounter a pathogen.

Generally speaking, the therapeutic cancer vaccines generate an anti-tumour response that is closer to a primary than a secondary immune response.

Image credit | iStock

Related Articles

COVID-19 not characterised by a cytokine storm

Inflammatory proteins known as cytokines play a crucial role in the immune response. If this response is too strong – a phenomenon known as “cytokine storm” – it can cause harm to the patient.

One-to-one: COVID response controvery

We hear from Professor Sunetra Gupta – the theoretical epidemiologist who believes in herd immunity and doesn’t believe in the lockdown.

"Three times risk for frontline healthcare workers"

Frontline healthcare workers with adequate personal protective equipment (PPE) have a three-fold increased risk of a positive SARS-CoV-2 test, compared with the public.